A randomized, prospective study of adjunctive ceftizoxime in preterm labor

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Pharmacology

Background:

• Preterm labor is a significant cause of neonatal morbidity and mortality.
• Tocolytic therapy is used to delay delivery in preterm labor, but its effectiveness can be limited.
• The role of antibiotics in managing preterm labor and preventing complications is an area of ongoing research.

Purpose of the Study:

• To evaluate the efficacy of ceftizoxime in prolonging gestation among patients receiving tocolysis for preterm labor.
• To determine if ceftizoxime influences the interval to delivery or the rate of delivery before 37 weeks' gestation.

Main Methods:

• A prospective, randomized, double-blinded, placebo-controlled trial.
• 117 eligible patients with preterm labor (24-35 weeks' gestation) receiving magnesium sulfate were randomized to ceftizoxime or placebo.
• Primary endpoint was prolongation of gestation; statistical analysis used t-tests and chi-squared analysis.

Main Results:

• No significant difference in the interval to delivery between the ceftizoxime group (34.5 days) and the placebo group (34.6 days) (p = 0.99).
• No difference in the rate of delivery before 37 weeks' gestation (60% vs. 58%, p = 0.91).
• Subanalyses in specific subgroups (e.g., those receiving >=9 doses, GBS-negative, or presenting at <=32 weeks) also showed no differences.

Conclusions:

• Ceftizoxime administration did not demonstrate any effect on prolonging the duration of pregnancy in women treated for preterm labor.
• The findings suggest that ceftizoxime is not beneficial for extending gestation in this clinical context.